About eNose
eNose is a Healthcare company based in Zutphen (Netherlands) founded in 2013. Electronic nose technology is developed for medical pathogen detection. Its focus areas include Life Sciences, Pulmonology, Medical Devices and Screening Devices.
Company details
eNose id developing an Electronic nose technology for high volume application. Its medical uses include use in detecting gases and pathogens and is used for sniffing out pathogens and in breath analysis for gastrointestinal diseases. Its has 3 products i.e. Aeonose for taking breath samples for screening and diagnosis purposes; Aetholab Electronic Nose equipment specialized on sniffing out headspaces, for example growth bottles containing pathogens; Aerekaprobe which is laboratory equipment and dedicated software for olfactory experiments using the electronic nose technology. The companys technology has applications in the diagnosis, screening, and monitoring of Gastrointestinal diseases, Head Neck cancers, Tuberculosis, Metritis, Breast cancer, and various lung diseases.
- Latest Funding Round$67.01K (USD), Grant
Apr 2019
- InvestorsEuropean Union
& 1 more
Funding Insights of eNose
- Total Rounds 2
- Last Round Grant — $67,008
- Investors Count 2
All 2 funding rounds of eNose with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $67,008 | Grant | – | – | |
| Dec 2015 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in eNose
eNose has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and Sallandsche Specialisten Cooperative.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sallandschespecialisten.nl | ||||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for eNose
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of eNose
3 dated milestones of eNose across 6 years, from founding to its latest funding, stage changes and deals.
- Founded eNose is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $67K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enose
Complete news archive for eNose
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about eNose
eNose was founded in 2013 and raised its 1st funding round 2 years after it was founded.
eNose is headquartered in Zutphen, Netherlands. It is registered at Zutphen, Gelderland, Netherlands.
eNose id developing an Electronic nose technology for high volume application. Its medical uses include use in detecting gases and pathogens and is used for sniffing out pathogens and in breath analysis for gastrointestinal diseases. Its has 3 products i.e. Aeonose for taking breath samples for screening and diagnosis purposes; Aetholab Electronic Nose equipment specialized on sniffing out headspaces, for example growth bottles containing pathogens; Aerekaprobe which is laboratory equipment and dedicated software for olfactory experiments using the electronic nose technology. The companys technology has applications in the diagnosis, screening, and monitoring of Gastrointestinal diseases, Head Neck cancers, Tuberculosis, Metritis, Breast cancer, and various lung diseases.
eNose has 2 investors. Key investors include European Union, and Sallandsche Specialisten Cooperative.